Blood Group Genotyping for Sickle Cell and Thalassaemi
This sits in the lower-middle of the Health & Social Care band — a mid-scale opportunity. Based on 32,734 valued Health & Social Care tenders in our corpus.
The main output of this programme is for blood group genotyping to become embedded into routine practice.
Primary objective (benefit) of doing so is to ensure patients with rare blood disorders have a minimise risk of adverse reactions through access to blood group genotyping.
What the supplier must deliver
Primary objective (benefit) of doing so is
Primary objective (benefit) of doing so is to ensure patients with rare blood disorders have a minimise risk of adverse reactions through access to blood group genotyping.
Derived from the notice text — always confirm against the original documents.
Make the case to bid
Reveal who to approach at NHS England, Leeds, and generate a go-to-market strategy from their news, accounts and people.
- OCID
- d966c341-a622-49a0-b6f4-29dbbc3b93bf
- Stage
- contract · Contract
- Source
- Contracts Finder
- Buyer ref
- CF-3178200D0O000000rwimUAA
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
Top suppliers & buyers in Health & Social Care
Assembling the market network…
NHS England, Leeds’s tender network
Assembling the network…